{"id":696,"date":"2022-10-03T17:21:05","date_gmt":"2022-10-03T15:21:05","guid":{"rendered":"https:\/\/opocringroup.it\/opocrin-spa-acquisisce-omikron-italia-srl\/"},"modified":"2022-10-04T18:31:16","modified_gmt":"2022-10-04T16:31:16","slug":"opocrin-s-p-a-acquires-omikron-italia-s-r-l","status":"publish","type":"post","link":"https:\/\/opocringroup.it\/en\/opocrin-s-p-a-acquires-omikron-italia-s-r-l\/","title":{"rendered":"Opocrin S.p.A. acquires Omikron Italia S.r.l."},"content":{"rendered":"[vc_row type=”full_width_background” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”light” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” advanced_gradient_angle=”0″ overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none” gradient_type=”default” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_spacing=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text]Opocrin S.p.A. becomes the <\/span>main shareholdres of Omikron Italia S.r.l.<\/b>, a pharmaceutical company that develops innovative <\/span>therapeutic solutions<\/b> for <\/span>vascular and ophthalmic pathologies.<\/b>\u00a0<\/span><\/p>\n

An initiative aimed at gradually responding to the therapeutic needs of vascular patients and those affected by major eye diseases.<\/span><\/p>\n

Omikron Italia S.r.l.<\/b> was born from the conviction that <\/span>vascular, ophthalmic and metabolic pathologies<\/b> require <\/span>further development<\/b> by searching innovative therapeutic solutions (drugs, medical devices, foods for special medical purposes, nutraceuticals).<\/span><\/p>\n

Therefore, Omikron Italia S.r.l. works to develop new therapeutic solutions, acquires <\/span>Marketing Authorization<\/b> of commercial drug and the <\/span>representation<\/b> of products available worldwide.<\/span><\/p>\n

Omikron Italia S.r.l. with its <\/span>16 years of experience <\/b>in the pharma field, undertakes to annualy invest <\/span>15% of its turnover in Research & Development<\/b>.<\/span><\/p>\n

The company operates in the pharmaceutical sector and is presented as a <\/span>partner of Specialists and Doctors of General Medicine<\/b> to respond exhaustively to the therapeutic needs of vascular patients and those who are affected by major eye and metabolic diseases.<\/span><\/p>\n

For <\/span>Opocrin Group<\/b>, this strengthens <\/span>a business model vertically integrated<\/b> in the production of <\/span>heparin<\/b> and <\/span>heparinoids<\/b>, guaranteeing the Group complete control of the quality of the product, starting from the mucosa to the active ingredient.<\/span>[\/vc_column_text][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"

[vc_row type=”full_width_background” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”light” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” advanced_gradient_angle=”0″ overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none” gradient_type=”default” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_spacing=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_shadow=”none” column_border_radius=”none” column_link_target=”_self”…<\/p>\n","protected":false},"author":2,"featured_media":517,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":{"0":"post-696","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news-en"},"_links":{"self":[{"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/posts\/696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/comments?post=696"}],"version-history":[{"count":1,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/posts\/696\/revisions"}],"predecessor-version":[{"id":712,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/posts\/696\/revisions\/712"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/media\/517"}],"wp:attachment":[{"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/media?parent=696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/categories?post=696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/opocringroup.it\/en\/wp-json\/wp\/v2\/tags?post=696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}